Hoping to leave the struggles of 2006 behind, DOV Pharmaceuticals Inc. is continuing to refocus its clinical pipeline. To that end, the Somerset, N.J.-based firm licensed rights to its late-stage pain drug, bicifadine, to XTL Biopharmaceuticals Ltd. in a deal potentially worth more than $130 million. (BioWorld Today)